New drug combo aims to outperform standard care in aggressive lung cancer

NCT ID NCT07625644

Not yet recruiting Disease control Sponsor: SystImmune Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive either the experimental combination or standard care. The main goal is to see if the new combination delays cancer progression or improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M14D1 and atezolizumab (drug combination)
What this could lead to: If successful, this could offer a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving how long patients live without their cancer growing.
What could go wrong: This is an early-stage trial (Phase 3) and the experimental drug combination may not work better than current standard care. Side effects from the new drug combination are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm metastatic malignant neoplasm small cell carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER LUNG CANCER METASTATIC LUNG CANCER STAGE IV SCLC SCLC, EXTENSIVE STAGE SMALL CELL CARCINOMA SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER EXTENSIVE STAGE

More trials for these conditions

Other studies related to the condition(s) this trial covers.